Published in J Oncol Pract on September 01, 2008
Let's Focus on Value. J Oncol Pract (2008) 0.75
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med (2004) 6.43
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
Ovarian cancer. Lancet (2009) 3.95
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.24
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation. Gynecol Oncol (2009) 2.15
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol (2004) 1.96
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.62
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. Gynecol Oncol (2007) 1.47
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol (2005) 1.45
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. Gynecol Oncol (2005) 1.41
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol (2010) 1.33
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Paclitaxel in cancer therapy. Expert Opin Pharmacother (2002) 1.26
The management of recurrent ovarian cancer. Semin Oncol (2007) 1.22
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer (2009) 1.18
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood (2007) 1.14
Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord (2003) 1.13
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab (2009) 1.13
Acanthosis nigricans with endometrial carcinoma: case report and review of the literature. Gynecol Oncol (2002) 1.10
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer (2009) 1.08
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2002) 1.08
Role of nutritional status in predicting quality of life outcomes in cancer--a systematic review of the epidemiological literature. Nutr J (2012) 1.07
Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol (2005) 1.06
The increasingly complex world of cancer patient advocacy organizations. Curr Oncol Rep (2008) 1.04
Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol (2006) 1.04
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol (2006) 1.03
The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management. Gynecol Oncol (2007) 1.02
Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol (2005) 1.01
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol (2014) 1.00
Viewing ovarian cancer as a "chronic disease": what exactly does this mean? Gynecol Oncol (2005) 1.00
Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol (2005) 0.99
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol (2002) 0.99
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol (2005) 0.97
An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol (2007) 0.94
Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol (2003) 0.94
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol (2014) 0.93
Clinically meaningful responses to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer. Case Rep Oncol (2013) 0.91
Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer (2007) 0.91
Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecol Oncol (2005) 0.90
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol (2003) 0.89
Running an ethical trial 60 years after the Nuremberg Code. Lancet Oncol (2007) 0.89
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 0.89
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol (2012) 0.89
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol (2011) 0.89
Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol (2005) 0.88
Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol (2003) 0.88
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study. Gynecol Oncol (2011) 0.87
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol (2008) 0.86
Hypersensitivity reactions to carboplatin. Gynecol Oncol (2002) 0.86
The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol Oncol (2006) 0.84
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol (2005) 0.84
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol (2004) 0.84
Palliation of symptomatic malignant ascites: an (often) unmet need. Oncology (2012) 0.84
Use of positron emission tomography scans in ovarian cancer: a diagnostic technique in search of an indication. J Clin Oncol (2005) 0.83
Molecular targeted therapy in ovarian cancer: what is on the horizon? Drugs (2011) 0.83
Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol (2004) 0.83
Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. Gynecol Oncol (2006) 0.83
Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology (2010) 0.82
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study. Gynecol Oncol (2010) 0.82
Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol (2003) 0.82
Fever of unknown origin and cancer: a clinically meaningful association. Lancet Oncol (2005) 0.81
CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial. Oncology (2010) 0.81
Apoptotic pathways of epothilone BMS 310705. Gynecol Oncol (2003) 0.81
Chemotherapy: A new standard combination for recurrent ovarian cancer? Nat Rev Clin Oncol (2010) 0.80
Initial experience with genomic profiling of heavily pretreated breast cancers. Ann Surg Oncol (2014) 0.80
Food and drug administration expanded access to treatment: implications for oncology patients. Cancer (2007) 0.80
The myth of measurable disease in ovarian cancer. J Clin Oncol (2003) 0.80
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol (2011) 0.79
Use of systemic antineoplastic drug therapy after regulatory agency approval. Oncology (2007) 0.79
Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol (2005) 0.79
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma. Oncology (2007) 0.79
Care of the incarcerated cancer patient. Curr Oncol Rep (2007) 0.79
Society of gynecologic oncologists position paper: breast cancer care. Gynecol Oncol (2008) 0.79
Prevention of paclitaxel-associated arthralgias and myalgias. J Support Oncol (2004) 0.79
The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy. Arch Gynecol Obstet (2010) 0.78
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecol Oncol (2009) 0.78
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. Int J Gynecol Cancer (2009) 0.78
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol (2011) 0.78
Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer. J Ovarian Res (2013) 0.78
A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies. Cancer Chemother Pharmacol (2015) 0.78
Care of pediatric cancers in the developing world: should this be a societal priority? Curr Oncol Rep (2005) 0.78
The research misconception. Int J Appl Philos (2004) 0.78
Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism. Case Rep Oncol (2012) 0.78
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2004) 0.77
Therapeutic intent in the conduct of phase I antineoplastic drug trials. Oncology (2009) 0.77
Outcomes when cancer treatment is delivered on, or off, a clinical trial: implications for generalizability of study results. Oncology (2011) 0.77
Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging? Curr Oncol Rep (2014) 0.77